Clinical trial · Observational
Immunotherapy for Hepatocellular Carcinoma
A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma
NCT06241326CI-TRIAL-00075880IFHCrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy-based Combination Therapies | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- retrospective cohort
- description
- The patients in the retrospective cohort are hepatocellular carcinoma patients who have been previously treated with immunotherapy-based combination regimens. It is anticipated that approximately 10,000 cases will be included.
- interventionNames
- Other: Immunotherapy-based Combination Therapies
- label
- prospective cohort
- description
- The patients included in the prospective cohort are hepatocellular carcinoma patients who are being evaluated by researchers to determine the potential benefits of undergoing immunotherapy-based combination treatment regimens. It is anticipated that approximately 1,000 cases will be enrolled.
- interventionNames
- Other: Immunotherapy-based Combination Therapies
Primary outcomes (1)
- measure
- Adverse events
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged after 18 years (18 is included). 2. Hepatocellular carcinoma diagnosed by pathology or imaging. 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens. 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations. 5. Patients voluntarily enroll in this study. Exclusion Criteria: 1. Pregnant or lactating women. 2. Other conditions regimented at investigators' discretion.
References
Publications (0)
Data not yet available
No reference posted for this study.